FindTrial
Sign In

Prospective study on Sugammadex and Neostigmine in reversal of neuromuscular blockade

Comparison of Sugammadex and Neostigmine for reversal of moderate neuromuscular blockade in paediatric patients:A randomised controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107558
Enrollment
60
Registered
2026-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Injection Sugammadex: 2mg/kg for reversal of moderate neuromuscular blockade Intervention2: Sugammadex: 2mg/kg for reversal of neuromuscular blockade administered through intravenous ro

Sponsors

Dr Raylene Dias
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade 1 and 2, age ranging from 2-12years undergoing abdominal and urological studies lasting upto 2 hours under general anaesthesia

Exclusion criteria

Exclusion criteria: Patient with malignant hyperthermia, burn patient disease affecting neuromuscular junction, known allergy, hypersensitivity to Neostigmine and Sugammadex, cardiovascular compromise, liver dysfunction, renal failure

Design outcomes

Primary

MeasureTime frame
Sugammadex has more efficacy in view to time and haemodynamic stability in comparison to NeostigmineTimepoint: time of application of reversal agent(t0) till time of extubation, monitoring haemodynamic parameters 5mins, 10mins,15mins,30mins,1hour, 2 hours after extubation—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactRaylene Dias

Seth GS Medical College and KEM Hospital

Ishitadreams@gmail.com9883732655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026